BsAb-armed T cells may help solid tumors fight back against cancer

Cancer in solid tumors often hides from the immune system, making treatments like CAR-T cells less effective. A recent review looked at a new approach called BsAb-armed T cells, which combine bispecific antibodies with T cells to better target these hard-to-reach cancers. The study compared this new method against standard CAR-T and bispecific antibody therapies. Results showed that BsAb-armed T cells might help T cells enter tumors more easily and stop the cancer from hiding or losing its targets. This could mean fewer cases of the cancer escaping treatment or losing the markers doctors use to find it. The review also noted that this approach might lower treatment-related toxicities, though specific safety data were not detailed in the report. Because this is a review of existing data rather than a new trial, the findings represent a summary of what is currently known. More research is needed to confirm these benefits in real-world patients before doctors can change how they treat solid tumors.